Dengue fever future or investigational therapies: Difference between revisions
No edit summary |
|||
| Line 3: | Line 3: | ||
==Overview== | ==Overview== | ||
Although there is no commercially available vaccine, there are several ongoing vaccine development programs. | |||
== | ==Vaccine development== | ||
There is no commercially available [[vaccine]] for the dengue [[flavivirus]]. However, one of the many ongoing vaccine development programs is the Pediatric Dengue Vaccine Initiative which was set up in 2003 with the aim of accelerating the development and introduction of dengue vaccine(s) that are affordable and accessible to poor children in endemic countries.<ref>{{cite web|url=http://www.pdvi.org/|title=Pediatric Dengue Vaccine Initiative website}}</ref> Thai researchers are testing a dengue fever vaccine on 3,000-5,000 human volunteers within the next three years after having successfully conducted tests on animals and a small group of human volunteers.<ref>{{cite web|url=http://english.people.com.cn/200509/05/eng20050905_206569.html|publisher=People's Daily Online|title=Thailand to test Mahidol-developed dengue vaccine prototype|date=2005-09-05|accessdate=2006-10-08}}</ref> and a number of other vaccine candidates are entering phase I or II testing.<ref>{{cite journal|title=Dengue vaccines approach the finish line|author=Edelman R|journal=Clin Infect Dis|volume=45|issue=S1|year=2007|pages=S56–S60|doi=10.1086/518148}}</ref> | |||
==Inhibitors of Viral Replication== | |||
Emerging evidence suggests that [[mycophenolic acid]] and [[ribivirin]] inhibit dengue replication. Initial experiments showed a fivefold increase in defective viral RNA production by cells treated with each drug.<sup>[http://vir.sgmjournals.org/cgi/content/full/87/7/1947]</sup> ''In vivo'' studies, however, have not yet been done. | Emerging evidence suggests that [[mycophenolic acid]] and [[ribivirin]] inhibit dengue replication. Initial experiments showed a fivefold increase in defective viral RNA production by cells treated with each drug.<sup>[http://vir.sgmjournals.org/cgi/content/full/87/7/1947]</sup> ''In vivo'' studies, however, have not yet been done. | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
Revision as of 13:49, 8 June 2014
|
Dengue Fever Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Dengue fever future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Dengue fever future or investigational therapies |
|
Dengue fever future or investigational therapies in the news |
|
Risk calculators and risk factors for Dengue fever future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Although there is no commercially available vaccine, there are several ongoing vaccine development programs.
Vaccine development
There is no commercially available vaccine for the dengue flavivirus. However, one of the many ongoing vaccine development programs is the Pediatric Dengue Vaccine Initiative which was set up in 2003 with the aim of accelerating the development and introduction of dengue vaccine(s) that are affordable and accessible to poor children in endemic countries.[1] Thai researchers are testing a dengue fever vaccine on 3,000-5,000 human volunteers within the next three years after having successfully conducted tests on animals and a small group of human volunteers.[2] and a number of other vaccine candidates are entering phase I or II testing.[3]
Inhibitors of Viral Replication
Emerging evidence suggests that mycophenolic acid and ribivirin inhibit dengue replication. Initial experiments showed a fivefold increase in defective viral RNA production by cells treated with each drug.[2] In vivo studies, however, have not yet been done.
References
- ↑ "Pediatric Dengue Vaccine Initiative website".
- ↑ "Thailand to test Mahidol-developed dengue vaccine prototype". People's Daily Online. 2005-09-05. Retrieved 2006-10-08.
- ↑ Edelman R (2007). "Dengue vaccines approach the finish line". Clin Infect Dis. 45 (S1): S56&ndash, S60. doi:10.1086/518148.